Bosulif
What is Bosulif (Bosutinib)?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, resulting in the constitutive activation of the BCR-ABL1 tyrosine kinase. The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the management of CML, trasforming it from a fatal disease to a chronic condition with excellent long-term outcomes for the majority ...
Summary: This CML disease registry (ASC4REAL-2) aims to gather evidence on the tolerability, safety, effectiveness, and patient-reported outcomes (PRO) in real-world healthcare from patients with Ph+-CML-CP treated with TKIs approved for 1L and 2L, including prospective follow-up for 5 years identifying and describing long-term treatment outcomes.
Summary: This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Related Latest Advances
Brand Information
- Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy
- Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy
- 100 mg: yellow, oval, biconvex, film-coated tablets debossed with "Pfizer" on one side and "100" on the other.
- 400 mg: orange, oval, biconvex, film-coated tablets debossed with "Pfizer" on one side and "400" on the other.
- 500 mg: red, oval, biconvex, film-coated tablets debossed with "Pfizer" on one side and "500" on the other.
- 50 mg: white body/orange cap with “BOS 50” printed on the body and “Pfizer” printed on the cap in black ink.
- 100 mg: white body/brownish-red cap with “BOS 100” printed on the body and “Pfizer” printed on the cap in black ink.
- Gastrointestinal toxicity
- Myelosuppression
- Hepatic toxicity
- Cardiovascular toxicity
- Fluid retention
- Renal toxicity

- BOSULIF capsules can be opened and the capsules contents mixed with room temperature applesauce or yogurt.
- Only use applesauce or yogurt.
- Swallow all of the mixture right away, without chewing.
- If you do not swallow the entire BOSULIF mixture, do not mix another dose. Wait until the next day to take your regularly scheduled dose.
- Take the BOSULIF mixture with a full meal.
Gather the following supplies:
- BOSULIF capsules
- small, clean container
- yogurt or applesauce
- teaspoon for mixing
- disposable gloves
- Store BOSULIF at room temperature between 68°F to 77°F (20°C to 25°C).
- Store the BOSULIF capsules in the original bottle.
- Ask your doctor or pharmacist about the right way to throw away outdated or unused BOSULIF.

(bosutinib) tablets

(bosutinib) tablets

(bosutinib) tablets

(bosutinib) capsules

(bosutinib) capsules




